Kinetics of parasite cysteine proteinase inactivation by NO-donors

Biochemical and Biophysical Research Communications

Volumn 315, Issue 3, 2004, Pages 710-718

  Bocedi, Alessio ^a,b   Gradoni, Luigi ^c   Menegatti, Enea ^d   Ascenzi, Paolo ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

Cruzipain; Falcipain; Leishmania infantum cysteine proteinase; NO donors; Parasite cysteine proteinase inactivation mechanism

Indexed keywords

4 ETHYL 2 HYDROXYIMINO 5 NITRO 3 HEXENAMIDE; ASCORBIC ACID; COUMARIN DERIVATIVE; CRUZIPAIN; CYSTEINE PROTEINASE; DANSYL CHLORIDE; DITHIONITE; FALCIPAIN; N ACETYL S NITROSOPENICILLAMINE; N ALPHA BENZYLOXYCARBONYLPHENYLALANYLARGININE(7 AMINO 4 METHYLCOUMARIN); NITRIC OXIDE; S NITROSOGLUTATHIONE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION KINETICS; ENZYME INACTIVATION; LEISHMANIA; LEISHMANIA INFANTUM; NITROSYLATION; NONHUMAN; PLASMODIUM; PRIORITY JOURNAL; TRYPANOSOMA;

LEISHMANIA INFANTUM; PLASMODIUM; TRYPANOSOMA;

EID: 1242295288     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.01.113     Document Type: Article

References (67)

1. Cox F.E.G. Modern Parasitology: A Textbook of Parasitology. second ed. 1993;Blackwell Science, Oxford.
2. Gilles H.M. Protozoal Diseases. 1999;Arnold, London.
3. McKerrow J.H., McGrath M.E., Engel J.C. The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. Parasitol. Today. 11:1995;279-282.
4. Francis S.E., Gluzman I.Y., Oksman A., Banerjee D., Goldberg D.E. Characterization of native falcipain, an enzyme involved in Plasmodium falciparum hemoglobin degradation. Mol. Biochem. Parasitol. 83:1996;189-200.
5. Cazzulo J.J., Stoka V., Turk V. Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi. Biol. Chem. 378:1997;1-10.
6. Coombs G.H., Mottram J.C. Hide G., Mottram J.C., Coombs G.H., Holmes P.H. Proteinases of Trypanosomes and Leishmania, in Trypanosomiasis and Leishmaniasis: Biology and Control. 1997;177-197 CAB International, Oxford.
7. Selzer P.M., Chen X., Chan V.J., Cheng M., Kenyon G.L., Kuntz I.D., Sakanari J.A., Cohen F.E., McKerrow J.H. Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp. Parasitol. 87:1997;212-221.
8. Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of Proteolytic Enzymes. 1998;Academic Press, London and San Diego.
9. Mottram J.C., Brooks D.R., Coombs G.H. Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions. Curr. Opin. Microbiol. 1:1998;455-460.
10. Scheidt K.A., Roush W.R., McKerrow J.H., Selzer P.M., Hansell E., Rosenthal P.J. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors. Bioorg. Med. Chem. 6:1998;2477-2494.
11. McKerrow J.H. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int. J. Parasitol. 29:1999;833-837.
12. McKerrow J.H., Engel J.C., Caffrey C.R. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem. 7:1999;639-644.
13. Cazzulo J.J. Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas disease. Curr. Top. Med. Chem. 2:2002;1261-1271.
14. Rosenthal P.J. Hydrolysis of erythrocyte proteins by proteases of malaria parasites. Curr. Opin. Hematol. 9:2002;140-145.
15. Venturini G., Colasanti M., Salvati L., Gradoni L., Ascenzi P. Nitric oxide inhibits falcipain, the Plasmodium falciparum trophozoite cysteine protease. Biochem. Biophys. Res. Commun. 267:2000;190-193.
16. Venturini G., Salvati L., Muolo M., Colasanti M., Gradoni L., Ascenzi P. Nitric oxide inhibits cruzipain, the major papain-like cysteine proteinase from Trypanosoma cruzi. Biochem. Biophys. Res. Commun. 270:2000;437-441.
17. Salvati L., Mattu M., Colasanti M., Scalone S., Venturini G., Gradoni L., Ascenzi P. NO donors inhibit Leishmania infantum cysteine proteinase activity. Biochim. Biophys. Acta. 1545:2001;357-366.
18. Ascenzi P., Salvati L., Bolognesi M., Colasanti M., Polticelli F., Venturini G. Inhibition of cysteine protease activity by NO-donors. Curr. Protein Pept. Sci. 2:2001;137-153.
19. Colasanti M., Salvati L., Venturini G., Ascenzi P., Gradoni L. Cysteine protease as a target for nitric oxide in parasitic organisms. Trends Parasitol. 17:2001;575.
20. Colasanti M., Gradoni L., Mattu M., Persichini T., Salvati L., Venturini G., Ascenzi P. Molecular bases for the anti-parasitic effect of NO. Int. J. Mol. Med. 9:2002;131-134.
21. Rockett K.A., Awburn M.M., Cowden W.B., Clark I.A. Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infect. Immun. 59:1991;3280-3283.
22. Vespa G.N.R., Cunha F.Q., Silva J.S. Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect. Immun. 62:1994;5177-5182.
23. Petray P., Castanos-Velez E., Grinstein S., Örn A., Rottenberg M.E. Role of nitric oxide in resistance and histopathology during experimental infection with Trypanosoma cruzi. Immunol. Lett. 47:1995;121-126.
24. Gobert A.P., Semballa S., Daulouede S., Lesthelle S., Taxile M., Veyret B., Vincendeau P. Murine macrophages use oxygen- and nitric oxide-dependent mechanisms to synthesize S-nitroso-albumin and to kill extracellular trypanosomes. Infect. Immun. 66:1998;4068-4072.
25. Zeina B., Banfield C., al-Assad S. Topical glyceryl trinitrate: a possible treatment for cutaneous leishmaniasis. Clin. Exp. Dermatol. 22:1997;244-245.
26. Lopez-Jaramillo P., Ruano C., Rivera J., Teran E., Salazar-Irigoyen R., Esplugues J.V., Moncada S. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet. 351:1998;1176-1177.
27. Davidson R.N., Yardley V., Croft S.L., Konecny P., Benjamin N. A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 94:2000;319-322.
28. Bogdan C., Gessner A., Solbach W., Röllinghoff M. Invasion, control and persistence of Leishmania parasites. Curr. Opin. Immunol. 8:1996;517-525.
29. Clark I.A., Rockett K.A. Nitric oxide and parasitic disease. Adv. Parasitol. 37:1996;1-56.
30. Brunet L.R. Nitric oxide in parasitic infections. Int. Immunopharmacol. 1:2001;1457-1467.
31. Ascenzi P., Gradoni L. Nitric oxide limits parasite development in vectors and in invertebrate intermediate hosts. IUBMB Life. 53:2002;121-123.
32. Waitumbi J., Warburg A. Phlebotomus papatasi saliva inhibits protein phosphatase activity and nitric oxide production by murine macrophages. Infect. Immun. 66:1998;1534-1537.
33. Kalvachova P., Hribalova V., Kodym P., Volf P. Modulation of murine lymphocyte responsiveness by the saliva of Rhodnius prolixus (Hemiptera: Reduviidae). J. Med. Entomol. 36:1999;341-344.
34. Rosenthal P.J., McKerrow J.H., Rasnick D., Leech J.H. Plasmodium falciparum: inhibitors of lysosomal cysteine proteinases inhibit a trophozoite proteinase and block parasite development. Mol. Biochem. Parasitol. 35:1989;177-184.
35. Lima A.P.C.A., Scharfstein J., Storer A.C., Ménard R. Temperature-dependent substrate inhibition of the cysteine proteinase (GP57/51) from Trypanosoma cruzi. Mol. Biochem. Parasitol. 56:1992;335-338.
36. Labriola C., Sousa M., Cazzulo J.J. Purification of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi by affinity chromatography. Biol. Res. 26:1993;101-107.
37. Stoka V., Nycander M., Lenarcic B., Labriola C., Cazzulo J.J., Bjork I., Turk V. Inhibition of cruzipain, the major cysteine proteinase of the protozoan parasite, Trypanosoma cruzi, by proteinase inhibitors of the cystatin superfamily. FEBS Lett. 370:1995;101-104.
38. Salvati L., Mattu M., Polticelli F., Tiberi F., Gradoni L., Venturini G., Bolognesi M., Ascenzi P. Modulation of the catalytic activity of cruzipain, the major cysteine proteinase from Trypanosoma cruzi, by temperature and pH. Eur. J. Biochem. 268:2001;3253-3258.
39. Xian M., Chen X., Liu Z., Wuang K., Wuang P.G. Inhibition of papain by S-nitrosothiols: formation of mixed disulfides. J. Biol. Chem. 275:2000;20467-20473.
40. Ignarro L., Lippton H., Edwards J.C., Baricos W.H., Hyman A.L., Kadowitz P.J., Gruetter C.A. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J. Pharmacol. Exp. Ther. 218:1981;739-749.
41. Kita Y., Hirasawa Y., Maeda K., Nishio M., Yoshida K. Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409. Eur. J. Pharmacol. 257:1994;123-130.
42. Williams D.L.H. The chemistry of S-nitrosothiols. Acc. Chem. Res. 32:1999;869-876.
43. Wyman J. Linked functions and reciprocal effects in hemoglobin: a second look. Adv. Protein Chem. 19:1964;223-286.
44. Ascenzi P., Menegatti E., Amiconi G. pH effects in biochemical reactions: what's the meaning of pK and midpoint? Biochem. Educ. 16:1988;93-94.
45. Polgár L., Halasz P. Current problems in mechanistic studies of serine and cysteine proteinases. Biochem. J. 207:1982;1-10.
46. Stoka V., McKerrow J.H., Cazzulo J.J., Turk V. Substrate inhibition of cruzipain is not affected by the C-terminal domain. FEBS Lett. 429:1998;129-133.
47. McGrath M.E., Eakin A.E., Engel J.C., McKerrow J.H., Craik C.S., Fletterick R.J. The crystal structure of cruzain: a therapeutic target for Chagas' disease. J. Mol. Biol. 247:1995;251-259.
48. Gillmor S.A., Craik C.S., Fletterick R.J. Structural determinants of specificity in the cysteine protease cruzain. Protein Sci. 6:1997;1603-1611.
49. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 28:2000;235-242.
50. Boeckmann B., Bairoch A., Apweiler R., Blatter M., Estreicher A., Gasteiger E., Martin M.J., Michoud K., O'Donovan C., Phan I., Pilbout S., Schneider M. The Swiss-Prot protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res. 31:2003;365-370.
51. Zhang H., Means G.E. S-Nitrosation of serum albumin: spectrophotometric determination of its nitrosation by simple S-nitrosothiols. Anal. Biochem. 237:1996;141-144.
52. Stamler J.S. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell. 78:1994;931-936.
53. Stamler J.S. S-nitrosothiols and the bioregulatory actions of nitrogen oxides through reactions with thiol groups. Curr. Top. Microbiol. Immunol. 196:1995;19-36.
54. Stamler J.S., Toone E.J., Lipton S.A., Sucher N.J. (S)NO signals: translocation, regulation, and a consensus motif. Neuron. 18:1997;691-697.
55. Stamler J.S., Hausladen A. Oxidative modifications in nitrosative stress. Nat. Struct. Biol. 5:1998;247-249.
56. Ascenzi P., Colasanti M., Persichini T., Muolo M., Polticelli F., Venturini G., Bordo D., Bolognesi M. Re-evaluation of amino acid sequence and structural consensus rules for cysteine-nitric oxide reactivity. Biol. Chem. 381:2000;623-627.
57. Stamler J.S., Simon D.I., Osborne J.A., Mullins M.E., Jaraki O., Michel T., Singel D.J., Loscalzo J. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc. Natl. Acad. Sci. USA. 89:1992;444-448.
58. Simon D.I., Mullins M.E., Jia L., Gaston B., Singel D.J., Stamler J.S. Polynitrosylated proteins: characterization, bioactivity, and functional consequences. Proc. Natl. Acad. Sci. USA. 93:1996;4736-4741.
59. Li J., Billiar T.R., Talanian R.V., Kim Y.M. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem. Biophys. Res. Commun. 240:1997;419-424.
60. Mohr S., Zech B., Lapetina E.G., Brune B. Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. Biochem. Biophys. Res. Commun. 238:1997;387-391.
61. Venturini G., Fioravanti E., Colasanti M., Persichini T., Ascenzi P. Cys25-nitrosylation inactivates papain. Biochem. Mol. Biol. Int. 46:1998;425-428.
62. Percival M.D., Ouellet M., Campagnolo C., Claveau D., Li C. Inhibition of cathepsin K by nitric oxide donors: evidence for the formation of mixed disulfides and a sulfenic acid. Biochemistry. 38:1999;13574-13583.
63. Saura M., Zaragoza C., McMillan A., Quick R.A., Hohenadl C., Lowenstein J.M., Lowenstein C.J. An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity. 10:1999;21-28.
64. Zech B., Wilm M., van Eldik R., Brune B. Mass spectrometric analysis of nitric oxide-modified caspase-3. J. Biol. Chem. 274:1999;20931-20936.
65. Persichini T., Colasanti M., Lauro G.M., Ascenzi P. Cysteine nitrosylation inactivates the HIV-1 protease. Biochem. Biophys. Res. Commun. 250:1998;575-576.
66. Sehajpal P.K., Basu A., Ogiste J.S., Lander H.M. Reversible S-nitrosation and inhibition of HIV-1 protease. Biochemistry. 38:1999;13407-13413.
67. Stamler J.S., Simon D.I., Jaraki O., Osborne J.A., Francis S., Mullins M., Singel D., Loscalzo J. S-Nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme. Proc. Natl. Acad. Sci. USA. 89:1992;8087-8091.